Palabras clave
Mycobacterium tuberculosis
Lipid Profile
Free Fatty Acid
Apolipoprotein B
Apolipoprotein B 48
Apolipoprotein B 100
Malondialdehyde
Resumen
Cardiovascular risk prediction is of high importance
for clinicians and patients to assess the risk of
developing cardiovascular disease (CVD), thereby
allowing for preventive interventions to be instituted
in those patients. Lipids and malondialdehyde (MDA)
status of individuals with active Mycobacterium
tuberculosis (MTB) infection were determined
before, after two, and six months’ treatment. This
prospective follow-up study recruited 159
tuberculosis (TB) treatment-naive individuals. They
were followed up on a six-month course of anti--
tuberculosis therapy (ATT).120 individuals completed
the study. Lipids and malondialdehyde were
measured before ATT, at two and six months post
treatment. MTB was detected by microscopy and
Genexpert methods. Lipids and malondialdehyde
levels were determined spectrophotometrically. The
mean levels of FFA, MDA, Apolipoprotein B, and B
48 were significantly lower in individuals with active
TB at 2 months and 6 months on ATT compared
with the baseline (p<0.05). The mean levels of
Apolipoprotein B100 were significantly higher in
individuals with active TB at 2 months and 6 months
following ATT compared with the baseline (p<0.05).
These findings showed reduced levels of MDA, Apo
B, and B 48 with increased levels of Apo B100 in
individuals with active MTB infection following
treatment. The observed significantly raised level of
Apo B100, even with treatment, indicates a higher
risk of cardiovascular disease. Lipid profile and apo
B100 levels significantly increased while
malondialdehyde, apolipoproteins B, and B 48
significantly decreased after treatment indicating a
good therapeutic response.
Referencias
Roth GA, Forouzanfar MH, Moran et al.
Demographic and epidemiologic drivers of global
cardiovascular mortality. N. Engl. J. Med. 2015,
, 1333–1341.
James K, Garry G. Developing a Research
Agenda for Primary Prevention of Chronic Lung
Diseases An NHLBI Perspective Am J Respir
Crit Care Med 2014, 189(7)762.
Benjamin EJ, Muntner P, Alonso et al. Heart
disease and stroke statistics—2019 update: A
report from the J. Am. Heart Assoc.Circulation
, 139, e56–e528.
Gazzola K., Reeskamp L, van den Born BJ.
Ethnicity, lipids, and cardiovascular disease. Curr.
Opin. Lipidol. 2017, 28, 225–230.
Szuszkiewicz-Garcia MM, Davidson JA.
Cardiovascular disease in diabetes mellitus, risk
factors, and medical therapy. Endocrinol. Metab.
Clin. N. Am. 2014, 43, 25–40.
Silverio A, Cavallo P, De Rosa R, Galasso G.
Big Health Data and Cardiovascular Diseases:
A Challenge for Research, an Opportunity for
Clinical Care. Front. Med. 2019, 6, 36.
Alkhalil M. Mechanistic Insights to Target
Atherosclerosis Residual Risk. Curr. Probl.
Cardiol. 2019, 46, 100432.
Arnett DK., Blumenthal RS, Albert, M.A.;
Buroker, A.B.; Goldberger, Z.D.; Hahn, E.J.;
Himmelfarb, C.D.; Khera, A.; Lloyd-Jones, D.;
McEvoy, J.W.; et al. 2019 ACC/AHA Guideline
on the Primary Prevention of Cardiovascular
Disease: A Report of the American College of
Cardiology/American Heart Association Task
Force on Clinical Practice Guidelines. J.Am. Coll.
Cardiol. 2019, 74, 1376–1414.
Hemmans MP, Ahn SA, Rousseau MF.
Atherogenic dyslipidemia [log (TG)/HDL-C] is
associated with residual vascular risk, beta–cell
function loss, and microangiopathy in type 2
diabetes females. Lipids Health Dis 2012,
(1)132.
Trompet S, Packard CJ, Jukema, JW. Plasma
apolipoprotein-B is an important risk factor for
CVD, and its assessment should be routine clinical
practice. Curr. Opin. Lipidol. 2018, 29, 51–52.
Libby P, Tabas I, Fredman, G, Fisher EA.
Inûammation and its resolution as determinants
of acute coronary syndromes. Circ. Res. 2014,
, 1867–1879.
Maguire EM, Pearce SWA, Xiao Q. Foam Cell
Formation. A New Target for Fighting
Atherosclerosis and Cardiovascular Disease.
Vascul. Pharmacol. 2019, 112, 54–71.
Constantinou C, Karavia EA, Xepapadaki et al.
Advances in high-density lipoprotein physiology:
surprises, overturns, and promises. Am J Physiol
EndocrinolMetab310: E1–E14, 2016. First
published 2015,doi:10.1152/ajpendo.00429.2015
Huaman MA, Henson D, Ticona E.Tuberculosis
and cardiovascular disease: linking the
epidemics. Tropical diseases travel medicine and
vaccines, 2015, 1(1)1. DOI 10.1186/s40794-015-
-5
Rodriguez Y, de Armas Y, Capo V, Wissmann G,
Goldani LZ, De Waard JH. Sudden death related
to tuberculous coronary arteritis. Int J Cardiol.
; 156 (2):e28–9. doi:10.1016/
j.ijcard.2011.08.002.
AC Ihim, SC Meludu, CC Onyenekwe, PO Manafa, AE Anyabolu and CN Akujobi
Nnodim, J., Anyadoh, S., Nwosu NE.(2011) The
antioxidant status and lipid peroxidation product
of newly diagnosed and six weeks follow-up
patients with pulmonary tuberculosis in Owerri,
Imo State, Nigeria. Asian Pacific Journal of
Tropical Disease, 1: 292-294.
Ihim AC, Nwosu DC, Nwanjo HU, Ozuruoke
DF, Nwobodo EI, Obi PC et al. Antioxidative
status of Nauclea latifolia leaves extract on
ciprofloxacin induced oxidative stress in rats. Int.
J. Inf. Res. Rev.2017; 04(04):33-37.
Oyedeji SO, Oguntuase N R, Esan A, Adesina
AA, Oke OT.Oxidative stress and lipid profile
status in pulmonary tuberculosis patients in South
Western Nigeria. Greener J Med Sci.2013;3 (6):
– 232.
Kapusta A, Kuczyñska B, Puppel K (2018)
Relationship between the degree of antioxidant
protection and the level of malondialdehyde in
high-performance Polish Holstein-Friesian cows
in the peak of lactation. PLoS ONE 13(3):
e 0 1 9 3 5 1 2 . h t t p s : / / d o i . o r g / 1 0 . 1 3 7 1
journal.pone.0193512 20. Chinedu IA,
Chukwuemeka MS,
Ihim AC, Meludu SC, Chinedum OC, Christian
EO. Evaluation of some antioxidants in
tuberculosis patients. Int J Health Sci Res. 2020;
(7):238246.
Liu A, Hu Y, Coates A. Sudden cardiac death
and tuberculosis - how much do we know?
Tuberculosis (Edinb). 2012; 92(4):307–13.
Doi:10.1016/ j.tube.2012.02.002.
Purnima P, Swasti J,Arvind A, Sachin M,
Devender Sc.Coronary arteritis as a cause of
sudden cardiac death in a young girl. Autops Case
Rep 2021; 11(1)67-70.
Pavic I, Radulovic P, Bujas T. Frequency of
tuberculosis at autopsies in a large hospital in
Zagreb, Croatia: a 10 year retrospective study.
Croatian Medical Journal 2012; 53(1)48-52.
Chung WS, Lin CL, Hung CT, Chu et al.
Tuberculosis increases the subsequent risk of
acute coronary syndrome: a nationwide
population-based cohort study. Int J Tuberc Lung
Dis. 2014;18(1):79–83. doi:10.5588/ijtld.13.0288.
Sheu JJ, Chiou HY, Kang JH, Chen YH, Lin HC.
Tuberculosis and the risk of ischemic stroke: a
-year follow-up study. Stroke. 2010; 41(2):244–
doi:10.1161/STROKEAHA.109.567735.
Ihim AC, Obi PC, Meludu C S, Onyenekwe CC,
Anyabolu E A, Njoku CM. Free Fatty Acid And
Lipid Profile In Active Tb, Latent Tb, Active Tb
And Hiv, Active Tb And Malaria Parasite In
Subjects In Anambra. Eur J Pharm Sci . 2018;
(11):506-511.
Ihim AC, Okeke O, Manafa PO, Ezejindu DN,
Nnodim J,Obi PC . Effect of Exposure To Soot
On Troponin I and Lipid Profile Levels. Eur J
Pharm Sci . 2016, 3(2): 05-10.
Ihim AC, Meludu SC, Onyenekwe CC, Anyabolu
AE, Akujobi CN. Serum apolipoprotein B
increased among tuberculosis patients compared
to healthy subjects. Univ Med 2021,40: 45-51.
doi: 10.18051/UnivMed.2021. v40.45-51
Curry SJ. Screening for Cardiovascular Disease
Risk With Electrocardiography US Preventive
Services Task Force Recommendation
Statement. JAMA. 2018;319(22):2308-2314.
doi:1 0 . 1 0 0 1 / ja ma . 2 0 1 8 . 6 8 4 8 :ht t p s :/ /
jamanetwork.com/ accessed on 06/28/2022
Valeska O, Soumyalekshmi N, Omar E, Claudio
A, Carlos S, Felipe A Z. Association between
insulin resistance and the development of
cardiovascular disease. Cardiovasc
Diabetol. 2018, 17: 122-127. doi: 10.1186/s12933-
-0762-4
Antonio A., Mario FM, Sandro A. Lipid
Peroxidation, Production, Metabolism, and
Signaling Mechanisms of Malondialdehyde and
-Hydroxy-2-Nonenal. Oxid Med Cell Longev
,1-31 https://doi.org/10.1155/2014/360438
Pugalendhi1V, Prema G, Panicker TMR, Paul
KM, Jagadeesan K, Tracy TAJ. Lipid
peroxidation and antioxidant status in patients of
end stage renal disease with and without
pulmonary tuberculosis. J. Int. Med. Sci. Acad.
, 25(4):225-227.
Gebremedhin G, Yemane A, Feyissa C, Atsbeha
G, Girmay M, Mistire W, Desta K. Lipid Profile
in tuberculosis Patients With and Wthout Human
Immunodeficiency Virus Infection. International
Journal of Chronic Diseases 2017, (3843291):1-
Prabakaran JJ, Biniam E, Matiwos A, Mussie
et al. Association of Dietary and Serum
Cholesterol with Active Pulmonary Tuberculosis:
A Hospital Based Study. International Journal of
Current Microbiology and Applied Sciences
,6 (12 ): 4056-4073.
Taparia P, Yadav D, Koolwal S, Mishra S. Study
of lipid profile in pulmonary tuberculosis patients
and relapse cases in relation with disease
severity.A pilot study. International Journal of
Sciences and Applied Research. 2015, 2(1): 41-
Albanna K B, Amr S, Donald W, Chantal V, Dick
M. Serum lipids as biomarkers for therapeutic
monitoring of latent tuberculosis infection. Eur.
Clin. Respir. J 2013,42: 547-550.
Lipids and Malondialdehyde in Individuals during and after Anti-Tuberculosis Therapy
Burtis AC, Ashwood ER, Bruns DE. Lipids,
Lipoproteins, Apolipoproteins and other
Cardiovascular Risk Factors in: Tietz
Fundamentals of Clinical Chemistry, 6th edition,
published by Elsevier, Sri Pratap Udyog, 274,
Capt. Gaur Marg, Sriniwaspuri, New Delhi India-
, 2008, chapter 23,pp.402-411.
Sniderman AD, Islam S, McQueen M, et al. Age
and cardiovascular risk attributable to
apolipoprotein B, low-density lipoprotein
cholesterol or non-high-density lipoprotein
cholesterol. J Am Heart Assoc 2016;5. doi.org/
1161/JAHA.116.003665